论文部分内容阅读
目的:探讨新生儿肺炎采用沐舒坦静脉滴注和雾化吸入治疗临床效果。方法:本次选取新生儿肺炎64例,均为我院2013年4月至2015年4月收治,随机分组,就沐舒坦静脉滴注治疗(对照组,n=30)与加用沐舒坦雾化吸入治疗(观察组,n=34)效果展开对比。结果:观察组选取的新生儿肺炎总有效率经统计示为91.2%,明显高于对照组76.7%,差异有统计学意义(P<0.05)。观察组咳嗽、肺部罗音、呼吸急促消失时间,住院时间均少于对照组,差异均有统计学意义(P<0.05)。结论:新生儿肺炎采用沐舒坦雾化吸入和静脉滴注,可取得理想疗效,加快患儿康复进程,对健康生长意义重大,值得广泛推广应用。
Objective: To investigate the clinical effect of mucosolvan intravenous drip and nebulized inhalation in neonatal pneumonia. Methods: Sixty-four cases of neonatal pneumonia were selected. All of them were treated in our hospital from April 2013 to April 2015 and were randomly divided into two groups: control group (n = 30) and mucosolvan Inhalation therapy (observation group, n = 34) the effect of contrast. Results: The total effective rate of neonatal pneumonia in the observation group was 91.2% as statistically, which was significantly higher than that of the control group (76.7%), the difference was statistically significant (P <0.05). Observation group cough, pulmonary rales, shortness of breath disappear time, hospital stay were less than the control group, the difference was statistically significant (P <0.05). Conclusion: Neonatal pneumonia with mucosolvan inhalation and intravenous drip, can achieve the desired effect, accelerate the recovery process in children, which is of great significance to the healthy growth and worthy of wide application.